Navigation Links
Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
Date:8/21/2008

me to recurrence, patient-reported outcomes, plasma biomarkers, safety and tolerability.

The study is enrolling patients with all HCC histologies. Patients will be randomized to receive 400 mg of Nexavar twice daily or matching placebo for up to four years. The study will be conducted at more than 200 sites in North America, South America, Europe and the Asia-Pacific region, including Japan. For information about enrolling in the study, please visit http://www.clinicaltrials.gov.

Hepatocellular carcinoma is the most common form of liver cancer and is responsible for about 90 percent of the primary malignant liver tumors in adults. Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally. More than 600,000 cases of liver cancer are diagnosed worldwide each year (more than 400,000 in China, South Korea, Japan and Taiwan, 54,000 in the European Union, and 15,000 in the United States) and the incidence is increasing. In 2002, approximately 600,000 people died of liver cancer including approximately 370,000 in China, South Korea and Japan, 57,000 in the European Union, and 13,000 in the United States.(1,2)

Currently there are no adjuvant treatments with proven benefit in HCC and half of the patients who have undergone surgical resection or local ablation will see their tumors return within three years and 70 percent will see their tumors return within five years.(3)

Nexavar's Differentiated Mechanism

Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) -- two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar is currently approved in m
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCarePharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
2. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
6. Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
7. Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
8. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
9. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
10. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern European ... established medical-device providers as well as new medical-device manufacturers ... while simultaneously looking at ways to reduce the cost ... distributors is one of the effective means to achieve ... distribution market in Eastern European and provides profiles of ...
(Date:9/30/2014)... , Sept. 30, 2014   Decision Resources ... claims data, anemic chronic kidney disease non-dialysis (CKD-ND) ... agent (ESA) medication. In addition, one-year persistency is ... Other key findings from the report ... Analysis of Erythropoiesis Stimulating Agents in Late Stage ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014  Arena ... (PLM) applications, today announced its Fall 2014 release, ... Scribe and Arena DataExtract – ... The newly available products are focused specifically on ... and the aggregation of a complete history of ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 2Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 3Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 4
(Date:9/30/2014)... Alan Mozes Health Day Reporter ... Colon cancer patients who are overweight or obese when ... developing a second weight-related cancer, new research suggests. , ... colon cancer recurrence, only the potential for developing other ... colorectal cancer survivors who reported being overweight or obese ...
(Date:9/30/2014)... Next to lung cancer, breast cancer is the leading ... American Cancer Society. That,s why so many medical professionals ... are imperfect at best: only a minority of suspicious ... results in lots of needless worry for women and ... of additional tests, including ultrasounds and biopsies. , ...
(Date:9/30/2014)... CO September 30, 2014 Keystone Symposia will ... the first in its 2014-15 Global Health Series ... the Sheraton Seattle Hotel immediately following the conclusion ... The four-day conference is part of the Keystone Symposia ... Gates Foundation, which has also funded travel awards for ...
(Date:9/30/2014)... A new study of 58 ... impact of stress on metabolism after eating a high-fat meal ... a fast food restaurant, about 930 calories and 60 grams ... minutes every hour for 7 hours, conducting the study twice ... had experienced a stressful event in their lives during the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Integrated ... wellness, is opening another new medical specialty practice through ... IMA Cardiology will be located within the company’s ... Abbud and Dr. Isaac Tawfik of American Heart Center, ... The new practice will offer Integrated Medicine Alliance patients ...
Breaking Medicine News(10 mins):Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:'Virtual breast' could improve cancer detection 2Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2
... in motor vehicle crashes is closely correlated to the severity ... at the Medical College of Wisconsin in Milwaukee. ... rupture, resulting in bleeding onto the surface of the retina. ... M.D., professors of ophthalmology at the Medical College, is published ...
... for Devastating ... Neurological Disease -, HAILEY, Idaho, June 23 Charles ... on June 17, 2008, for,his support to find a cure for the ... or Parkinson,s disease. Chuck has had PSP for several years,and, despite his ...
... Pacific Corporation, one of,this country,s best kept secrets in ... as part of its current offering to existing and ... review all,financial information up to the second from their ... "We are excited to be able to offer this ...
... Findley Davies, Inc., a human,resources consulting firm, ... Association of Business Communicators (IABC) Cleveland Vision,Awards. For ... HCR,ManorCare, Findley Davies Communication Solutions practice received an,Award ... Davies Communication Solutions practice also received an Award ...
... Insurance,Company ("The Standard"), a subsidiary of StanCorp Financial ... insurance products for employers with as,few as 10 ... line, The,Standard now provides employers with the opportunity ... term disability, life, dental,and vision insurance from a ...
... patients who need little, if any, immune suppression , , ... called HLA-G dimer plays a powerful role in preventing ... Medical College of Georgia researchers say. , They ... mice and are currently studying whether this molecule is ...
Cached Medicine News:Health News:Severe retinal hemorrhaging is linked to severe motor vehicle crashes 2Health News:Advertising Hall of Famer Charles D. Peebler Receives Honor for Work Supporting Cure for Progressive Supernuclear Palsy 2Health News:Oregon Based First Pacific Corporation Launches New E-Tools Program for Dentists 2Health News:Findley Davies Receives IABC Vision Awards 2Health News:The Standard Introduces Three Flexible Vision Insurance Plans 2Health News:The Standard Introduces Three Flexible Vision Insurance Plans 3Health News:Immune Molecule Key to Preventing Organ Rejection 2
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
Medicine Products: